Regional Analysis
Global Preclinical Imaging Market- Regional Insights
- North America is expected to be the largest market for preclinical imaging during the forecast period, accounting for over 35.7% of the market share in 2023. The preclinical imaging market in North America is driven by increasing drug development activities and rising demand for non-invasive techniques for studying disease pathology.
- Asia Pacific market is expected to be the second-largest market for preclinical imaging market, accounting for over 25.2% of the market share in 2023. The Asia Pacific preclinical imaging market is witnessing significant growth due to rising incidence of diseases and increasing investments in research & development (R&D) by pharmaceutical companies.
- Europe market is expected to be the fastest-growing market for preclinical imaging market, with a share of 19.0% during the forecast period. The Europe preclinical imaging market has been witnessing steady growth driven by factors such as rising focus on personalized medicine. However, high costs of preclinical imaging systems are a major challenge, thus limiting widespread adoption.
| Geographies covered: |
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
|
U.S.: 
U.K. : 
India : 
